OPTIMMAL
An Open-Label, Non-Randomized, Multicenter, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 30 patients (estimated)
- Sponsors
- Stanford University Cancer Institute (Palo Alto)
- Collaborators
- Janssen Pharmaceuticals
- Tags
- Bispecific Antibody, GPRC5D, Maintenance
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1920
- NCT Identifier
- NCT06461988
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.